Table 4.
Multivariate Analysis for Factors Associated with Survival Outcomes
| Characteristic | Patients who Underwent BCT or TM | Patients who Underwent BCT | ||||
|---|---|---|---|---|---|---|
| HR | p Value | 95% CI | HR | p Value | 95% CI | |
| Disease-free survival | ||||||
| SLND alone | NS | NS | ||||
| Clinical stage T2 | 3.1 | <0.001 | 1.8–5.4 | 3.5 | 0.001 | 1.7–7.5 |
| Adjuvant chemotherapy | ||||||
| Yes | Referent | Referent | ||||
| No | NS | 2.9 | 0.03 | 1.1–7.2 | ||
| Adjuvant hormonal therapy | ||||||
| Yes | Referent | |||||
| No | 2.1 | 0.009 | 1.2–3.6 | NS | ||
| Presence of LVI | 2.0 | 0.01 | 1.1–3.3 | NS | ||
| Age, y* | NS | 0.9 | <0.001 | 0.9–0.97 | ||
| Overall survival | ||||||
| SLND alone | NS | |||||
| Clinical stage T2 | 2.2 | 0.003 | 1.3–1.5 | 2.3 | 0.03 | 1.1–4.9 |
| Adjuvant chemotherapy | ||||||
| Yes | Referent | Referent | ||||
| No | 2.6 | <0.0001 | 1.5–4.3 | 3.7 | <0.0001 | 1.8–7.5 |
*
Treated as a continuous variable.
BCT, breast-conserving therapy; CI indicates confidence interval; ER, estrogen receptor; HR, hazard ratio; LVI, lymphovascular invasion; NS, not significant; SLND, sentinel lymph node dissection; TM, total mastectomy.